
Evogene Ltd. (NASDAQ:EVGN) (TASE: EVGN) Q2 2022 revenue was $312,000, an increase of 131% compared to $135,000 in the same period the previous year. Revenues were primarily due to the initial sales of Lavie Bio's Thrivus product (previously branded as Result) and sales of Canonic products in the Israeli market.